GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolife Sciences Inc (OTCPK:BLFE) » Definitions » Cash, Cash Equivalents, Marketable Securities

Biolife Sciences (Biolife Sciences) Cash, Cash Equivalents, Marketable Securities : $0.04 Mil (As of May. 2008)


View and export this data going back to 2005. Start your Free Trial

What is Biolife Sciences Cash, Cash Equivalents, Marketable Securities?

Biolife Sciences's quarterly cash, cash equivalents, marketable securities declined from Nov. 2007 ($0.41 Mil) to Feb. 2008 ($0.02 Mil) but then increased from Feb. 2008 ($0.02 Mil) to May. 2008 ($0.04 Mil).

Biolife Sciences's annual cash, cash equivalents, marketable securities declined from Nov. 2005 ($1.25 Mil) to Nov. 2006 ($0.16 Mil) but then increased from Nov. 2006 ($0.16 Mil) to Nov. 2007 ($0.41 Mil).


Biolife Sciences Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Biolife Sciences's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolife Sciences Cash, Cash Equivalents, Marketable Securities Chart

Biolife Sciences Annual Data
Trend Nov04 Nov05 Nov06 Nov07
Cash, Cash Equivalents, Marketable Securities
0.09 1.25 0.16 0.41

Biolife Sciences Quarterly Data
Nov04 Feb05 May05 Aug05 Nov05 Feb06 May06 Aug06 Nov06 Feb07 May07 Aug07 Nov07 Feb08 May08
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.10 0.41 0.02 0.04

Biolife Sciences Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Biolife Sciences  (OTCPK:BLFE) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Biolife Sciences Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Biolife Sciences's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Biolife Sciences (Biolife Sciences) Business Description

Industry
Traded in Other Exchanges
N/A
Address
2831 Street Rose Parkway, No. 200, Henderson, NV, USA, 89052
Biolife Sciences Inc is a commercialization accelerator, licensor and developer of innovative and disruptive technologies for the healthcare, beauty and food and beverage industry sectors. The company's technologies include antimicrobial copper air filters and copper-infused textiles. Its revenues are primarily generated from the sale of sanitation products.
Executives
Arthur Viola director, 10 percent owner, officer: CEO

Biolife Sciences (Biolife Sciences) Headlines

From GuruFocus

Rhino Novi Announces Name Change and New CEO

By Marketwired Marketwired 09-15-2020